透景生命 (300642.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

14.2x

EV/EBITDA

49.1x

Market Cap

CNY 2.19B

MomentumView details →

1D Return

−1.53%

YTD Return

−5.82%

RSI (14)

57.9

ValuationView details →

P/E (Fwd)

14.2x

EV/EBITDA

49.1x

Market Cap

CNY 2.19B

RSI (14)

57.9

MomentumView details →

1D Return

−1.53%

YTD Return

−5.82%

ProfitabilityView details →

Gross Margin

69.70%

Net Margin

−0.66%

EBITDA Margin

15.88%

ROE (TTM)

−0.17%

ROA (TTM)

−0.12%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

−11.24%

EPS YoY

—

FCF YoY

+43.61%

Revenue CAGR 3Y

−20.20%

EPS CAGR 3Y

−69.39%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.10

EPS Surprise

−48.56%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.31

Avg Surprise (4Q)

−48.56%

Rev Surprise

−52.11%

Capital & dividendView details →

Debt/Equity

0.26x

Current Ratio

5.38x

Quick Ratio

4.77x

Div Yield

0.87%

Div Rate

CNY 0.15

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

371.54M

Net Income (TTM)

−2.44M

Op. CF (TTM)

135.10M

Next earningsOct 28, 2026 →

Latest newsMore news →

Shanghai Rongzhen Investment Group, a specific shareholder of Tellgen Corporation, announced plans to reduce its stake by up to 0.77% of total shares via centralized bidding between September 9 and December 8, 2026.1d ago

Tellgen Corporation reported its 2026 half-year results: revenue of 187.3439 million yuan, up 17.78% year-on-year; net profit attributable to shareholders of 11.4765 million yuan, up 315.92% year-on-year, partly due to the consolidation of Wuhan Kanglu Biotechnology Co., Ltd.10d ago

Similar companies

龙泉股份002671.SZ 雪祺电气001387.SZ 纽泰格301229.SZ 高斯贝尔002848.SZ 晨化股份300610.SZ 欣龙控股000955.SZ Find similar companies →

Latest newsMore news →

Shanghai Rongzhen Investment Group, a specific shareholder of Tellgen Corporation, announced plans to reduce its stake by up to 0.77% of total shares via centralized bidding between September 9 and December 8, 2026.1d ago Tellgen Corporation reported its 2026 half-year results: revenue of 187.3439 million yuan, up 17.78% year-on-year; net profit attributable to shareholders of 11.4765 million yuan, up 315.92% year-on-year, partly due to the consolidation of Wuhan Kanglu Biotechnology Co., Ltd.10d ago